MEPOLIZUMAB IMPROVES AND SUSTAINS CLINICAL BENEFITS IN PATIENTS WITH SEVERE ASTHMA, INDEPENDENT OF BLOOD EOSINOPHIL COUNT AT BASELINE: REAL-WORLD ANALYSIS OF REALITI-A RESULTS AT 2 YEARS